Research map: Combining fruquintinib with TAS-102 as a promising strategy: antitumor activity in preclinical colorectal and gastric cancer xenograft models

Back to the article

Papers in this map

  1. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy · Rakesh K. Jain · 2001 · 2197 citations · Cited by this paper
  2. Tumor budding and tumor-associated lymphocytic response as histopathological indicators of high-risk disease in head and neck cutaneous squamous cell carcinoma · 2026 · Related
  3. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites · Sheau-Yann Shieh · 2000 · 969 citations · Cited by this paper
  4. Integrative transcriptomic and experimental analyses identifies SDF4 as an astrocyte-expressed regulator of glioma progression through PI3K-AKT signaling · 2026 · Related
  5. Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer · Gerald W. Prager · 2023 · 464 citations · Cited by this paper
  6. Investigation of the significance and role of androgen receptor expression in basal/squamous type urothelial carcinoma cell line J82 cells · 2026 · Related
  7. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer · Jin Li · 2018 · 415 citations · Cited by this paper
  8. Precision oncology meets Generative AI: assessing large language models in multidisciplinary GIST tumor boards · 2026 · Related
  9. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study · Arvind N. Dasari · 2023 · 351 citations · Cited by this paper
  10. Senescence-related immunosuppressive gene MFAP2 orchestrates stromal-immune crosstalk and immunotherapy resistance in gastric cancer · 2026 · Related
  11. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy · Shuang Qin · 2019 · 345 citations · Cited by this paper
  12. The impact of STAS on recurrence-free and overall survival in T1-2N0 adenocarcinomas: a single-center retrospective study · 2026 · Related
  13. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor–Associated Hypertension and Vascular Disease · Arvind Kant Pandey · 2017 · 341 citations · Cited by this paper
  14. Despite improved overall stratification, the 9th edition stage IIIA category remains prognostically heterogeneous: insights from a T3N2a subgroup analysis · 2026 · Related
  15. Unraveling the Role of Angiogenesis in Cancer Ecosystems · Iratxe Zuazo-Gaztelu · 2018 · 285 citations · Cited by this paper
  16. Characterisation of a novel p53 mutation (p53N263Tfs*7) associated with li-fraumeni syndrome · 2026 · Related
  17. TAS-102, a novel antitumor agent: A review of the mechanism of action · Heinz‐Josef Lenz · 2015 · 163 citations · Cited by this paper
  18. Trends in treatment and survival of stage IV non-squamous NSCLC from 2010 to 2022 · 2026 · Related
  19. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer · Jen Jen Yeh · 2009 · 162 citations · Cited by this paper
  20. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy · Qiaoling Sun · 2014 · 160 citations · Cited by this paper
  21. Lymphatic vessels in cancer · Lothar C. Dieterich · 2022 · 157 citations · Cited by this paper
  22. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts · Hiroshi Tsukihara · 2015 · 111 citations · Cited by this paper
  23. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor · Paul Mésange · 2014 · 86 citations · Cited by this paper
  24. Two Birds, One Stone: Double Hits on Tumor Growth and Lymphangiogenesis by Targeting Vascular Endothelial Growth Factor Receptor 3 · Ming‐Chuan Hsu · 2019 · 68 citations · Cited by this paper
  25. Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer · Andrew James Weickhardt · 2015 · 66 citations · Cited by this paper
  26. Different significance between intratumoral and peritumoral lymphatic vessel density in gastric cancer: a retrospective study of 123 cases · Xiaolei Wang · 2010 · 53 citations · Cited by this paper
  27. Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor Fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics · Yi Gu · 2014 · 46 citations · Cited by this paper
  28. Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression · Kazuaki Matsuoka · 2018 · 35 citations · Cited by this paper
  29. Synchronous vascular endothelial growth factor protein profiles in both tissue and serum identify metastasis and poor survival in colorectal cancer · Chien-Chih Yeh · 2019 · 13 citations · Cited by this paper
  30. Evaluation of a Novel Combination Therapy, Based on Trifluridine/Tipiracil and Fruquintinib, against Colorectal Cancer · Mamoru Nukatsuka · 2023 · 9 citations · Cited by this paper
  31. Pharmacokinetics and protein binding of cholesterol-conjugated heteroduplex oligonucleotide · Yukitake Yoshioka · 2025 · 8 citations · Cited by this paper

Source: OpenAlex (CC0)